TPCW
VRTX icon

TD Private Client Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

TD Private Client Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$676K Sell
1,361
-463
-25% -$205K 0.01% 439
2026
Q1 		$815K Sell
1,824
-19
-1% -$8.86K 0.02% 402
2025
Q4 		$836K Buy
1,843
+52
+3% +$22.4K 0.02% 393
2025
Q3 		$701K Sell
1,791
-2,327
-57% -$973K 0.02% 426
2025
Q2 		$1.83M Sell
4,118
-2,107
-34% -$971K 0.05% 257
2025
Q1 		$3.02M Buy
6,225
+8
+0.1% +$3.73K 0.08% 174
2024
Q4 		$2.5M Sell
6,217
-7,470
-55% -$3.46M 0.07% 197
2024
Q3 		$6.37M Buy
13,687
+3,494
+34% +$1.68M 0.18% 84
2024
Q2 		$4.78M Sell
10,193
-2,623
-20% -$1.14M 0.15% 105
2024
Q1 		$5.36M Sell
12,816
-1,065
-8% -$450K 0.18% 93
2023
Q4 		$5.65M Sell
13,881
-1,216
-8% -$449K 0.2% 83
2023
Q3 		$5.25M Sell
15,097
-985
-6% -$344K 0.23% 86
2023
Q2 		$5.66M Sell
16,082
-1,073
-6% -$362K 0.24% 85
2023
Q1 		$5.41M Buy
17,155
+2,043
+14% +$613K 0.24% 93
2022
Q4 		$4.36M Sell
15,112
-149
-1% -$45.4K 0.21% 110
2022
Q3 		$4.42M Sell
15,261
-503
-3% -$145K 0.23% 102
2022
Q2 		$4.44M Buy
15,764
+4,750
+43% +$1.27M 0.22% 108
2022
Q1 		$2.87M Buy
11,014
+308
+3% +$73.1K 0.12% 177
2021
Q4 		$2.35M Sell
10,706
-649
-6% -$126K 0.1% 213
2021
Q3 		$2.06M Buy
11,355
+4,113
+57% +$803K 0.09% 227
2021
Q2 		$1.46M Buy
7,242
+6,516
+898% +$1.36M 0.06% 283
2021
Q1 		$156K Sell
726
-7,733
-91% -$1.7M 0.01% 533
2020
Q4 		$2M Sell
8,459
-1,962
-19% -$450K 0.1% 215
2020
Q3 		$2.84M Buy
10,421
+65
+0.6% +$17.9K 0.16% 138
2020
Q2 		$3.01M Buy
10,356
+9,580
+1,235% +$2.6M 0.18% 128
2020
Q1 		$185K Buy
776
+118
+18% +$27.1K 0.01% 428
2019
Q4 		$144K Buy
+658
New +$133K 0.01% 482

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

TD Private Client Wealth's VRTX Position: Q2 2026 in Review

TD Private Client Wealth reduced its Vertex Pharmaceuticals (VRTX) stake by 25% in Q2 2026, selling an estimated $205K and leaving 1,361 shares worth $676K. The position accounts for 0.01% of the portfolio, ranked #439.

TD Private Client Wealth first reported a position in VRTX in Q4 2019 and has held it in 27 quarters since. The position peaked at $6.37M in Q3 2024. 1,756 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • TD Private Client Wealth held 1,361 shares of Vertex Pharmaceuticals worth $676K as of Q2 2026.
  • TD Private Client Wealth sold 463 Vertex Pharmaceuticals shares in Q2 2026, an estimated $205K.
  • Vertex Pharmaceuticals made up 0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #439 holding.
  • TD Private Client Wealth first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • TD Private Client Wealth's Vertex Pharmaceuticals position peaked at $6.37M in Q3 2024.
  • 1,756 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.